ArticleHeliyon2022

Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study.

Lei Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.